Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK2330811 in diffuse cutaneous systemic sclerosis
NL-OMON49656Phase 2Completed
- Sponsor
- GSK
- Start
- Jan 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in systemic sclerosis (SSc) comparing GSK2330811 with Placebo (2 arms). Primary endpoints: Adverse events, Laboratory safety parameters and 2 more. Started Jan 2019; status: completed.
02
Drugs
gsk2330811
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on NL-OMON49656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49656.